☆ 4.7 Article

Anti-PD-1/PD-L1 for nasopharyngeal carcinoma: a comprehensive analysis of registered trials on ClinicalTrials.gov

FRONTIERS IN PHARMACOLOGY (2023)

Related references

Note: Only part of the references are listed.

Editorial Material Oncology

Recurrent nasopharyngeal carcinoma: hyperfractionation of IMRT improves outcomes

David Killock

NATURE REVIEWS CLINICAL ONCOLOGY (2023)

Add to Collection

Editorial Material Oncology

Envisioning clinical trials as complex interventions

Kristian D. Stensland et al.

Summary: Clinical trials are crucial for modern healthcare and have both societal and individual benefits. However, these trials often fail to achieve their goals and have low enrollment rates. The authors propose applying implementation science to clinical trials to improve their conduct and increase their effectiveness.

CANCER (2022)

Add to Collection

Article Oncology

Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial

Yuan Zhang et al.

Summary: This study demonstrated that induction chemotherapy before concurrent chemoradiotherapy significantly improved overall survival in patients with locally advanced nasopharyngeal carcinoma, without increasing the risk of late toxicities. Tumor response to induction chemotherapy and pretreatment cell-free Epstein-Barr virus DNA may serve as useful indicators for individualized treatment.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Review Oncology

Current status and advances of immunotherapy in nasopharyngeal carcinoma

Jian-Ying Xu et al.

Summary: This review provides a comprehensive overview of the rationale, current status, advances, and challenges of immunotherapy in nasopharyngeal carcinoma (NPC). It focuses on the clinical application and advances of PD-1 inhibitor monotherapy and its combination with chemotherapy, as well as other immunotherapy approaches. The review also describes the clinical studies' status and challenges of immune checkpoint inhibitors (ICIs)-based immunomodulatory strategies in local advanced NPC, and highlights the biomarker application for personalized immunotherapy of NPC.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Cross-Sectional Survey of Clinical Trials of Stem Cell Therapy for Heart Disease Registered at ClinicalTrials.gov

Rong Yang et al.

Summary: The study analyzed 241 clinical trials of stem cell therapy for heart diseases and found that most of them are interventional studies with small sample sizes and short durations. Some trials lacked clear funding sources, and the majority did not publish their study results.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Medicine, General & Internal

Comparison of Publication of Pediatric Probiotic vs Antibiotic Trials Registered on ClinicalTrials.gov

Madison Riddell et al.

Summary: This study found that probiotic trials are less likely to be published compared to antibiotic trials, which may have implications for the results of meta-analyses of probiotic trials. No other study characteristics were associated with publication status.

JAMA NETWORK OPEN (2021)

Add to Collection

Review Oncology

A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma

Anne W. M. Lee et al.

Summary: Plasma EBV DNA has potential clinical applications in nasopharyngeal carcinoma, including screening, prognosis assessment, and treatment monitoring. However, the major limitation lies in the harmonisation of measurement methods for consistent comparability.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Review Oncology

Nasopharyngeal carcinoma: an evolving paradigm

Kenneth C. W. Wong et al.

Summary: Over the past three decades, significant progress has been made in understanding the molecular biology and treatment of nasopharyngeal carcinoma (NPC), an Epstein-Barr virus (EBV)-associated cancer. Technological advances have led to the introduction of proton therapy and other contemporary radiotherapy approaches, with continued efforts to determine the optimal sequencing of chemotherapy with radiotherapy through decades of clinical trials.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

Add to Collection

Review Oncology

Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence

Raju K. Vaddepally et al.

CANCERS (2020)

Add to Collection

Article Pharmacology & Pharmacy

Characteristics of Clinical Trials relating to COVID-19 registered at ClinicalTrials.gov

Yuhui Wang et al.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2020)

Add to Collection

Article Primary Health Care

Trends in FDA drug approvals over last 2 decades: An observational study

Angelika Batta et al.

JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE (2020)

Add to Collection

Review Oncology

Immunotherapy as sensitizer for local radiotherapy

Ben G. L. Vanneste et al.

ONCOIMMUNOLOGY (2020)

Add to Collection

Article Oncology

Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy

Quynh Thu Le et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Trials Focusing on Drug Control and Prevention of Ventilator-Associated Pneumonia: A Comprehensive Analysis of Trials Registered on ClinicalTrials.gov

Lingmin Chen et al.

FRONTIERS IN PHARMACOLOGY (2019)

Add to Collection

Review Medicine, General & Internal

Nasopharyngeal carcinoma

Yu-Pei Chen et al.

LANCET (2019)

Add to Collection

Review Oncology

Management of locally recurrent nasopharyngeal carcinoma

Anne W. M. Leea et al.

CANCER TREATMENT REVIEWS (2019)

Add to Collection

Review Oncology

The Reciprocity between Radiotherapy and Cancer Immunotherapy

Yifan Wang et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection

Article Oncology

T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

Patrick A. Ott et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Characterization of PD-L1 and PD-1 Expression and CD8+Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma

Noppadol Larbcharoensub et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2018)

Add to Collection

Review Oncology

Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians

Sophie Outh-Gauer et al.

CANCER TREATMENT REVIEWS (2018)

Add to Collection

Letter Oncology

Comparison between PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, and atezolizumab) in pretreated NSCLC patients: Evidence from a Bayesian network model

Yingcheng Wu et al.

INTERNATIONAL JOURNAL OF CANCER (2018)

Add to Collection

Editorial Material Medicine, General & Internal

Randomization in Clinical Trials Permuted Blocks and Stratification

Kristine Broglio

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)

Add to Collection

Article Oncology

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)

Brigette B. Y. Ma et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Oncology

A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer

Wei You et al.

JOURNAL OF CANCER (2018)

Add to Collection

Review Oncology

A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics A Review

Julia A. Beaver et al.

JAMA ONCOLOGY (2018)

Add to Collection

Article Oncology

Changes in Disease Failure Risk of Nasopharyngeal Carcinoma over Time: Analysis of 749 Patients with Long-Term Follow-Up

Xu Liu et al.

JOURNAL OF CANCER (2017)

Add to Collection

Article Oncology

Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity

Valsamo Anagnostou et al.

CLINICAL CANCER RESEARCH (2017)

Add to Collection

Article Medicine, General & Internal

Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?

Robert Kemp et al.

BMC MEDICINE (2017)

Add to Collection

Article Oncology

Integrated pathway analysis of nasopharyngeal carcinoma implicates the axonemal dynein complex in the Malaysian cohort

Yoon-Ming Chin et al.

INTERNATIONAL JOURNAL OF CANCER (2016)

Add to Collection

Review Health Care Sciences & Services

Perceived information gain from randomized trials correlates with publication in high-impact factor journals

Evangelos Evangelou et al.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2012)

Add to Collection

Review Oncology

The blockade of immune checkpoints in cancer immunotherapy

Drew M. Pardoll

NATURE REVIEWS CANCER (2012)

Add to Collection

Review Medicine, General & Internal

Randomisation to protect against selection bias in healthcare trials

R. Kunz et al.

COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2007)

Add to Collection

Review Oncology

A listing of human tumor antigens recognized by T cells

N Renkvist et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.